Aceclofenac - CAS 89796-99-6
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Aceclofenac
Catalog Number:
89796-99-6
Synonyms:
Preservex
CAS Number:
89796-99-6
Description:
Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) analog of Diclofenac. It is used for the relief of pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. It has higher anti-inflammatory action than conventional NSAIDs. It is a cytokine inhibitor. It works by blocking the action of a substance in the body called cyclo-oxygenase.
Molecular Weight:
354.18
Molecular Formula:
C16H13Cl2NO4
COA:
Inquire
MSDS:
Inquire
Targets:
COX
Chemical Structure
CAS 89796-99-6 Aceclofenac

Related COX Products


CAS 31842-01-0 Indoprofen

Indoprofen
(CAS: 31842-01-0)

Indoprofen, a non-steroidal anti-inflammatory drug, is a cyclooxygenase inhibitor and used for the treatment of pain and inflammation and spinal muscular atroph...

CAS 70374-39-9 Lornoxicam

Lornoxicam
(CAS: 70374-39-9)

A non-steroidal COX-1/COX-2 inhibitor; A nonsteroidal anti-inflammatory drug

CAS 169590-42-5 Celecoxib

Celecoxib
(CAS: 169590-42-5)

A highly selective COX-2 inhibitor

CAS 853-34-9 Kebuzone

Kebuzone
(CAS: 853-34-9)

Kebuzone is a non-steroidal anti-inflammatory drug. It also has analgesic, antipyretic, and platelet-inhibitory activities. Kebuzone is a cyclooxygenase inhibit...

CAS 169590-41-4 Deracoxib

Deracoxib
(CAS: 169590-41-4)

Deracoxib is a non-steroidal anti-inflammatory drug (NSAID) of the coxib class. Deracoxin is a selective cyclooxygenase-2 (COX-2) inhibitor used in the treatmen...

CAS 103-90-2 Acetaminophen

Acetaminophen
(CAS: 103-90-2)

A selective COX-2 inhibitor

CAS 13710-19-5 Tolfenamic Acid

Tolfenamic Acid
(CAS: 13710-19-5)

A COX-2 inhibitor with IC50 of 0.2 μM

CAS 198470-84-7 Parecoxib

Parecoxib
(CAS: 198470-84-7)

The prodrug Parecoxib as well as its active metabolite val have a specific affinity to the cannabinoid (CB) receptor measured in CB1-expressing HEK 293 cells an...

CAS 78213-16-8 Diclofenac Diethylamine

Diclofenac Diethylamine
(CAS: 78213-16-8)

Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug taken to reduce inflammation and as an analgesic reducing pain in certain conditions.

CAS 181695-72-7 Valdecoxib

Valdecoxib
(CAS: 181695-72-7)

A selective COX-2 inhibitor

CAS 2438-72-4 Bufexamac

Bufexamac
(CAS: 2438-72-4)

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.Bufexamac is a drug used as an anti-inflammatory agent on the skin, as well as rectally. Comm...

CAS 50-78-2 Aspirin

Aspirin
(CAS: 50-78-2)

A salicylate and irreversible COX1 and COX2 inhibitor

BMS-347070
(CAS: 197438-73-6)

BMS-347070 is a COX-2 inhibitor, initially developed for the treatment for Colorectal cancer.

CAS 41340-25-4 Etodolac

Etodolac
(CAS: 41340-25-4)

A non-selective inhibitor of COX

CAS 123663-49-0 Iguratimod

Iguratimod
(CAS: 123663-49-0)

Iguratimod(T-614) is a selective inhibitor of cyclo-oxygenase-2 (COX-2), and inhibits the production of interleukin-1 (IL-1), IL-6, IL-8 and tumour necrosis fac...

CAS 69-72-7 Salicylic acid

Salicylic acid
(CAS: 69-72-7)

Salicylic acid is a natural product extract from Willow bark, well known as an antiinflammatory inhibitor of cyclooxygenase activity. It is widely used in organ...

CAS 36062-05-2 Hexahydrocurcumin

Hexahydrocurcumin
(CAS: 36062-05-2)

Extract from the rhizomes of Curcuma longa L, shows cytotoxic effect, may prove useful in cancer prevention.

CAS 141505-32-0 Ibuprofen lysinate

Ibuprofen lysinate
(CAS: 141505-32-0)

Dexibuprofen is a Cyclooxygenase inhibitor originated by Gebro Pharma GmbH. It is a non-steroidal anti-inflammatory drug as the active dextrorotatory enantiomer...

CAS 116686-15-8 FK 3311

FK 3311
(CAS: 116686-15-8)

A selective COX-2 inhibitor

CAS 15687-27-1 Ibuprofen (Dolgesic)

Ibuprofen (Dolgesic)
(CAS: 15687-27-1)

An inhibitor of COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively

Reference Reading


1.Glucocorticoids and chronotherapy in rheumatoid arthritis.
Cutolo M1. RMD Open. 2016 Mar 18;2(1):e000203. doi: 10.1136/rmdopen-2015-000203. eCollection 2016.
It is evident that the morning symptoms of rheumatoid arthritis (RA) are linked to the circadian abnormal increase in night inflammation, favoured by inadequate cortisol secretion under conditions of active disease. Therefore, exogenous glucocorticoid treatment is recommended in RA at low doses since it may partially act like a 'replacement therapy'. The prevention/treatment of the night upregulation of the immune/inflammatory reaction (and related flare of cytokine synthesis) has been shown to be more effective when exogenous glucocorticoid administration is obtained with a night-time-release formulation. Large-scale trials documented that modified-release prednisone has greater efficacy then morning prednisone for long-term low-dose glucocorticoid treatment in patients with RA, showing at least a more significant reduction in morning joint stiffness. Interestingly, despite a considerably higher cost than conventional prednisone, chronotherapy with night-time-release prednisone was recognised as a cost-effective option for patients with RA not on glucocorticoids who are eligible for therapy with biological disease-modifying antirheumatic drugs (DMARDs).
2.Development and validation of an LC-ESI-MS/MS method for the simultaneous quantification of naproxen and sumatriptan in human plasma: application to a pharmacokinetic study.
Brêtas JM1, César IC2, Brêtas CM1, Teixeira LS3, Bellorio KB3, Mundim IM3, Pianetti GA1. Anal Bioanal Chem. 2016 Mar 28. [Epub ahead of print]
A sensitive and fast liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) method was developed and validated for the simultaneous quantification of naproxen and sumatriptan in human plasma. A simple liquid-liquid extraction procedure, with a mixture of ethyl acetate, methyl tert-butyl ether, and dichloromethane (4:3:3, v/v), was used for the cleanup of plasma. Naratriptan and aceclofenac were employed as internal standards. The analyses were carried out using an ACE C18 column (50 × 4.6 mm i.d.; particle size 5 μm) and a mobile phase consisting of 2 mM aqueous ammonium acetate with 0.025 % formic acid and methanol (38:62, v/v). A triple-quadrupole mass spectrometer equipped with an electrospray source in the positive mode was set up in the selective reaction monitoring mode to detect the ion transitions m/z 231.67 → m/z 185.07, m/z 296.70 → m/z 157.30, m/z 354.80 → m/z 215.00, and m/z 336.80 → m/z 97.94 for naproxen, sumatriptan, aceclofenac, and naratriptan, respectively.
3.Development and evaluation of decorated aceclofenac nanocrystals.
Park JJ1, Meghani N1, Choi JS2, Lee BJ3. Colloids Surf B Biointerfaces. 2016 Mar 10;143:206-212. doi: 10.1016/j.colsurfb.2016.03.022. [Epub ahead of print]
This study was aimed at achieving enhanced solubility of aceclofenac (ACF) in nanocrystaline forms (ACF-NC) and evaluating the effects of ACF-NC on cell viability. Decorated ACF-NC were prepared by nano-precipitation with stabilizers. Three kinds of stabilizers were investigated: Tween 80, Poloxamer 407, and PEG 6000. The crystal structure and morphology of ACF-NC were characterized by field emission scanning electron microscopy (FE-SEM) and differential scanning calorimetry (DSC). The solubility of ACF-NC and ACF (pure) was evaluated in different media (pH 1.2 and pH 6.8 buffers and distilled water [DW]). A drug release study was performed in PBS for 24h. Cell viability was evaluated for 24h using a human colon cancer cell-line (HCT-116) and a human breast cancer cell-line (MCF-7). Decorated ACF-NC with a mean size of 725nm were successfully prepared. The solubility of the decorated ACF-NC were 4-7 times higher than that of ACF in DW and pH 6.
4.Novel elastic membrane vesicles (EMVs) and ethosomes-mediated effective topical delivery of aceclofenac: a new therapeutic approach for pain and inflammation.
Sharma G1, Goyal H1, Thakur K1, Raza K2, Katare OP1. Drug Deliv. 2016 Mar 10:1-11. [Epub ahead of print]
CONTEXT: Aceclofenac (ACE) is a systematically designed drug, developed to circumvent the concerns associated with diclofenac. But ACE is also associated with non-steroidal anti-inflammatory drug (NSAIDs)-tagged side effects, although of decreased amplitude.